药物研发公司Summit与Akeso达成协议，以50亿美元获得突破性创新双特异性抗体许可-动脉橙

药物研发公司Summit与Akeso达成协议，以50亿美元获得突破性创新双特异性抗体许可

2022-12-06 globenewswire 等4家媒体报道商业合作





2022年12月6日，药物研发公司Summit Therapeutics Inc.宣布与Akeso Biopharma Inc.达成最终合作协议，授权其突破性双特异性抗体ivonescimab使用。该协议支持Summit的使命，即开发和商业化突破性的肿瘤管道产品，旨在改善严重未满足医疗需求的患者的生活质量。对于Akeso来说，这笔交易代表着将其高度创新的抗体引入美国、加拿大、欧洲和日本等市场的机会，这是Akeso成为全球生物制药组织的战略目标的重要一步。

关联公司

 Summit Therapeutics康方生物

2022-12-06 Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

globenewswire
2022-12-06 Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

prnewswire
2022-12-06 Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody$500 Million Upfront Payment to Activate the Partnership for Ivonescimab

biospace
2022-12-06 Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

biospace